Tech Company Inital Public Offerings
NGM Biopharmaceuticals IPO
On 4/3/2019, NGM Biopharmaceuticals went public.
Transaction Overview
Company Name
Announced On
4/3/2019
Transaction Type
IPO
Amount
$106,656,000
Proceeds Purpose
The firm says it will use the net proceeds from the IPO as follows: to fund the development of the NGM282 program and related product candidates; to fund the development of our other programs, including our early-stage drug discovery programs and pre-commercialization activities; and the remainder for working capital and general operating expenses.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
333 Oyster Point Blvd.
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
NGM Biopharmaceuticals (Nasdaq: NGM) is a privately-held drug discovery company committed to the identification and development of transformational biologics for diabetes, obesity, muscle wasting and other cardiometabolic diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
William Rieflin
Chief Executive Officer
David Woodhouse
Chief Medical Officer
Alex DePaoli
Chief Scientific Officer
Jin-Long Chen
Vice President
Wenyan Shen
VP - R & D
Hui Tian
Browse more venture capital transactions:
Prev: 4/3/2019: OnScale venture capital transaction
Next: 4/3/2019: Bill.com venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs